US court refuses Ranbaxy Laboratories' appeal to block ANDA nod for 2 drugs

27 Nov 2014 Evaluate

DC Federal Court in the US has not granted Ranbaxy Laboratories' temporary restraining order to block the US health regulator from approving other ANDAs for generic versions of digestive disorder medicine Nexium and anti-viral Valcyte. However, the court ordered the parties to the suit to agree upon a schedule for filing additional legal briefs, addressing Ranbaxy’s request for a preliminary injunction by November 21, 2014. Earlier, the company had filed a complaint against the US FDA in D.C. Federal Court and had also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1536.40
Dr. Reddys Lab 5837.65
Cipla 1405.00
Zydus Lifesciences 1104.45
Lupin 1657.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.